ByTrending Posts
Can Insilico Medicine and China Medical System Accelerate…
Executive SummaryIn a strategic expansion of their collaboration in February 2026, Insilico Medicine and China Medical System Holdings…
Can Angelini’s $120M AI Alliance with Quiver Bioscience…
Executive SummaryIn a strategic push to strengthen its neuroscience pipeline, Angelini Pharma has entered a multiyear collaboration with…
Is Takeda’s $1.7B Bet on Iambic Therapeutics the…
Executive SummaryIn one of the largest AI-driven drug discovery collaborations to date, Takeda Pharmaceutical has entered a multiyear…
Can Hippocratic AI’s Acquisition of Grove AI Trigger…
Executive SummaryAt the 2026 JPM Healthcare Conference in San Francisco, Hippocratic AI announced the acquisition of Grove AI,…
Innovent and Eli Lilly Expand Strategic Alliance to…
Shanghai, China – February, 2026 – Innovent Biologics Inc today announced a new strategic collaboration with Eli Lilly…
Eli Lilly to Acquire Orna Therapeutics in Deal…
Indianapolis, IN – February 9, 2026 – Eli Lilly and Company today announced it has entered into a…
AstraZeneca Reports 2025 Performance with Strong Brand Momentum…
AstraZeneca today announced its full-year 2025 results, reflecting continued growth across oncology, cardiovascular-renal-metabolism (CVRM), respiratory & immunology, and…
GSK Reports Full-Year 2025 Results with Strategic Portfolio…
GSK today reported its full-year performance for 2025 and outlined its strategic approach to long-term growth across vaccines,…
Roche Reports Full-Year 2025 Results and Provides Strategic…
Roche today announced its full-year 2025 performance and outlined its strategic positioning across key therapeutic areas. Roche maintained…
Trending Posts
Latest Stories
How Does Bristol Myers Squibb Secure Multi-Billion Dollar Growth Through 8 Key Oncology Catalysts by 2030?
Bristol Myers Squibb strategically positions for next-decade dominance through its deep pipeline featuring 5 multi-billion-dollar assets (pumitamig, iberdomide, mezigdomide,…
How Does Gilead Secure $10B+ Oncology Growth Through 3 Strategic Acquisitions by 2030?
How Does Gilead Secure $10B+ Oncology Growth Through 3 Strategic Acquisitions by 2030? Gilead Sciences…
How Does AbbVie Pioneer Oncology Transformation While Sustaining Immunology Leadership Through 2030?
AbbVie strategically positions for multi-franchise dominance through its $59B immunology base (Skyrizi/Rinvoq offsetting Humira’s $17B erosion) while aggressively building oncology…
How Does Johnson & Johnson Weaponize Oncology Supremacy for $50 Billion Revenue by 2030?
Johnson & Johnson orchestrates a “full-spectrum oncology domination” strategy across its Innovative Medicine division, positioning for #1…
Gallery
